

DOCUMENT-IDENTIFIER: US 20040220100 A1

TITLE: Multi-component biological transport systems

0127258

CLAIMS:

68. A composition according to claim 1 in which the biologically active protein is a botulinum toxin.
69. A composition according to claim 68 in which the botulinum toxin is selected from botulinum toxin serotypes A, B, C, D, E, F and G.
70. A composition according to claim 68 in which the botulinum toxin comprises a botulinum toxin derivative.
71. A composition according to claim 68 in which the botulinum toxin comprises a recombinant botulinum toxin.
73. A kit according to claim 72 wherein the biologically active agent is a botulinum toxin.
90. A method according to claim 80 in which the therapeutic protein is a botulinum toxin.
91. A method according to claim 90 in which the botulinum toxin is selected from botulinum toxin serotypes A, B, C, D, E, F and G.
92. A method according to claim 90 in which the botulinum toxin comprises a botulinum toxin derivative.
93. A method according to claim 90 in which the botulinum toxin comprises a recombinant botulinum toxin.
94. A method according to claim 90 in which the botulinum toxin is administered to provide an aesthetic and/or cosmetic benefit to the subject.
95. A method according to claim 90 in which the botulinum toxin is administered to the subject for prevention or reduction of symptoms associated with muscle spasm or cramping.
96. A method according to claim 90 in which the botulinum toxin and the positively charged carrier are administered topically to a site on the face of the subject.
97. A method according to claim 90 in which the botulinum toxin and the positively charged carrier are administered topically to a site on the subject other than the face.
130. A composition according to claim 98 in which the antigen is a botulinum toxin.
131. A composition according to claim 130 in which the botulinum toxin is selected from botulinum toxin serotypes A, B, C, D, E, F and G.
132. A composition according to claim 130 in which the botulinum toxin comprises a botulinum toxin derivative.
133. A composition according to claim 130 in which the botulinum toxin comprises a recombinant

botulinum toxin.

174. A method according to claim 141 in which the antigen suitable for immunization is a botulinum toxin.

175. A method according to claim 174 in which the botulinum toxin is selected from botulinum toxin serotypes A, B, C, D, E, F and G.

176. A method according to claim 174 in which the botulinum toxin comprises a botulinum toxin derivative.

177. A method according to claim 174 in which the botulinum toxin comprises a recombinant botulinum toxin.

227. A composition according to claim 221 in which the targeting agent recognizes melanoma.

235. A method according to claim 229 in which the targeting agent recognizes melanoma.

236. A method according to claim 229 in which the composition is applied for screening of patients at risk for melanoma.

237. A method according to claim 229 in which the composition is applied to aid surgical excision of melanoma.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)